A5031852566- Pulmonary Hypertension Research and Treatments
- Microbial Metabolic Engineering and Bioproduction
- Immune cells in cancer
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- interferon and immune responses
- Colorectal Cancer Treatments and Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer Research and Treatments
- Enzyme Catalysis and Immobilization
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Biofuel production and bioconversion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Pancreatic and Hepatic Oncology Research
- Bacterial Genetics and Biotechnology
- Gastric Cancer Management and Outcomes
- Bacteriophages and microbial interactions
- Metabolomics and Mass Spectrometry Studies
- Polymer Surface Interaction Studies
- Diagnosis and treatment of tuberculosis
- CNS Lymphoma Diagnosis and Treatment
- Chemokine receptors and signaling
- Metal complexes synthesis and properties
Gossamer Bio (United States)
2021-2025
Ferring Pharmaceuticals (United States)
2020
Genomatica (United States)
2009-2016
Howard Hughes Medical Institute
2013
University of California, Berkeley
2007
Max Planck Institute of Colloids and Interfaces
1999
Signalling through platelet-derived growth factor receptor (PDGFR), colony-stimulating 1 (CSF1R) and mast/stem cell kit (c-KIT) plays a critical role in pulmonary arterial hypertension (PAH). We examined the preclinical efficacy of inhaled seralutinib, unique small-molecule PDGFR/CSF1R/c-KIT kinase inhibitor clinical development for PAH, comparison to proof-of-concept inhibitor, imatinib.Seralutinib imatinib potency selectivity were compared. Inhaled seralutinib...
Summary Background Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, transcription factor with protective roles at the epithelial layer inflamed gut. Aims To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy patients active UC. Methods This double‐blind, placebo‐controlled study randomised 2:1 receive oral...
The transition from viral latency to lytic growth involves complex interactions among host and factors, the extent which physiology is buffered virus during induction of lysis not known. A reasonable hypothesis that should be evolutionarily selected ensure health throughout minimize its chance reproductive failure. To address this question, we collected transcriptional profiles Escherichia coli bacteriophage lambda lysogenic by UV light.We observed a temporally coordinated program phage gene...
Ultrathin layers of a new metallosupramolecular iron(II) coordination−polyelectrolyte containing 1,4-bis(2,2':6',2' '-terpyridine-4'-yl)benzene (1) have been prepared by alternating adsorption from dilute solution. Adsorption on oppositely charged surfaces and layer-by-layer growth were investigated in situ surface plasmon resonance spectroscopy. The average film thickness 1 is 18 Å good agreement with molecular layer. Water can penetrate the resulting an increased thickness. kinetics show...
Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population end points persist.What is the effect DP2 antagonist GB001 on worsening in patients with moderate to severe eosinophilic asthma?In this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, or placebo was added standard-of-care...
Although anti-tumor activities of type I interferons (IFNs) have been recognized for decades, the molecular mechanisms contributing to clinical response remain poorly understood. The complex functions these pleiotropic cytokines include stimulation innate and adaptive immune responses against tumors as well direct inhibition tumor cells. In high-grade, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, nadofaragene firadenovec, a non-replicating adenovirus...
<b>Introduction:</b> Seralutinib, a novel, inhaled kinase inhibitor with anti-inflammatory and anti-proliferative effects, met the primary endpoint of reduction in pulmonary vascular resistance phase 2 TORREY trial PAH (NCT04456998) has potential to treat remodeling. This abnormal remodeling includes distal pruning proximal arterial dilation. Quantitative analysis these features is possible CT imaging. <b>Methods:</b> The substudy used thin-section, volumetric non-contrast chest CTs followed...